TriNetX
TriNetX, Inc. operates a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a suite of tools designed to optimize clinical trial design and recruitment processes. Its platform integrates real-time access to longitudinal clinical data, including electronic medical records and clinical documentation, enabling users to analyze patient populations effectively. Key offerings include TriNetX Live, which allows researchers to explore patient data, and TriNetX Research, which provides access to comprehensive clinical data. Additionally, the platform incorporates advanced analytics and natural language processing to extract relevant information from clinical notes. By streamlining trial design and enhancing site selection, TriNetX helps accelerate the development and approval of new therapies. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.
Custodix N.V. specializes in data protection solutions for the eHealth sector, focusing on the secure management of sensitive health data. The company offers a variety of products, including Custodix Anonymisation Services (CATS) for de-identifying data, the Patient Identity Management System (PAMS) for managing patient identifiers from multiple sources, and Custodix Identity and Access Management (CIAM) for overseeing identity and access in distributed environments. Additionally, Custodix provides services that enable the secure re-use of electronic health records for clinical research, as well as consultancy on data privacy and protection, ensuring compliance with European and US data protection regulations. Founded in 2000 and headquartered in Sint-Martens-Latem, Belgium, Custodix operates as a subsidiary of TriNetX, Inc. since 2019.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.